|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms E Walmsley
|
|||
|
b)
|
Position/status
|
Chief Executive Officer
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2015 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
12,482
(Deferred)
|
|
||
|
|
£0.0000
|
8,614
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
21,096
|
|||
|
Aggregated
volume Price
|
£0.0000
|
||||
|
e)
|
Date
of the transaction
|
2018-02-16
|
|||
|
f)
|
Place
of the transaction
|
n/a
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms E Walmsley
|
|||
|
b)
|
Position/status
|
Chief Executive Officer
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 16 February 2018 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.1563
|
5,868 (Deferred)
|
|
||
|
|
£13.1563
|
4,050 (Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
9,918
|
|||
|
Aggregated
volume Price
|
£13.1563
|
||||
|
e)
|
Date
of the transaction
|
2018-02-16
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr R Connor
|
|||
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2015 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
9,142
(Deferred)
|
|
||
|
|
£0.0000
|
6,308
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
15,450
|
|||
|
Aggregated
volume Price
|
£0.0000
|
||||
|
e)
|
Date
of the transaction
|
2018-02-16
|
|||
|
f)
|
Place
of the transaction
|
n/a
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
||||
|
a)
|
Name
|
Mr R Connor
|
|
|||
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 16 February 2018 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£13.1028
|
4,384
(Deferred)
|
|
|||
|
|
£13.1200
|
3,026
(Matching)
|
|
|||
|
|
|
|
|
|||
|
d)
|
Aggregated
information
|
7,410
|
|
|||
|
Aggregated
volume Price
|
£13.1114
|
|
||||
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|||
|
|
|
|
|
|
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr S Dingemans
|
|||
|
b)
|
Position/status
|
Chief Financial Officer
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2015 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
17,435
(Deferred)
|
|
||
|
|
£0.0000
|
12,030
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
29,465
|
|||
|
Aggregated
volume Price
|
£0.0000
|
||||
|
e)
|
Date
of the transaction
|
2018-02-16
|
|||
|
f)
|
Place
of the transaction
|
n/a
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
||||
|
a)
|
Name
|
Mr S Dingemans
|
|
|||
|
b)
|
Position/status
|
Chief Financial Officer
|
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 16 February 2018 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£13.1236
|
8,360
(Deferred)
|
|
|||
|
|
£13.1230
|
5,768
(Matching)
|
|
|||
|
|
|
|
|
|||
|
d)
|
Aggregated
information
|
14,128
|
|
|||
|
Aggregated
volume Price
|
£13.1233
|
|
||||
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|||
|
|
|
|
|
|
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr N Hirons
|
|||
|
b)
|
Position/status
|
SVP, Global Ethics and Compliance
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2015 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
6,402
(Deferred)
|
|
||
|
|
£0.0000
|
4,418
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
10,820
|
|||
|
Aggregated
volume Price
|
£0.0000
|
||||
|
e)
|
Date
of the transaction
|
2018-02-16
|
|||
|
f)
|
Place
of the transaction
|
n/a
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
||||
|
a)
|
Name
|
Mr N Hirons
|
|
|||
|
b)
|
Position/status
|
SVP, Global Ethics and Compliance
|
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 16 February 2018 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£13.1068
|
3,070
(Deferred)
|
|
|||
|
|
£13.1118
|
2,120
(Matching)
|
|
|||
|
|
|
|
|
|||
|
d)
|
Aggregated
information
|
5,190
|
|
|||
|
Aggregated
volume Price
|
£13.1093
|
|
||||
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|||
|
|
|
|
|
|
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr D Redfern
|
|||
|
b)
|
Position/status
|
Chief Strategy Officer
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2015 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
10,258
(Deferred)
|
|
||
|
|
£0.0000
|
7,078
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
17,336
|
|||
|
Aggregated
volume Price
|
£0.0000
|
||||
|
e)
|
Date
of the transaction
|
2018-02-16
|
|||
|
f)
|
Place
of the transaction
|
n/a
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
||||
|
a)
|
Name
|
Mr D Redfern
|
|
|||
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 16 February 2018 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£13.1800
|
4,822
(Deferred)
|
|
|||
|
|
£13.1800
|
3,328
(Matching)
|
|
|||
|
|
|
|
|
|||
|
d)
|
Aggregated
information
|
8,150
|
|
|||
|
Aggregated
volume Price
|
£13.1800
|
|
||||
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|||
|
|
|
|
|
|
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms C Thomas
|
|||
|
b)
|
Position/status
|
SVP, Human Resources
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2015 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
13,805
(Deferred)
|
|
||
|
|
£0.0000
|
9,525
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
23,330
|
|||
|
Aggregated
volume Price
|
£0.0000
|
||||
|
e)
|
Date
of the transaction
|
2018-02-16
|
|||
|
f)
|
Place
of the transaction
|
n/a
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms C Thomas
|
|||
|
b)
|
Position/status
|
SVP, Human Resources
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 16 February 2018 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.1180
|
6,489
(Deferred)
|
|
||
|
|
£13.1180
|
4,478
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
10,967
|
|||
|
Aggregated
volume Price
|
£13.1180
|
||||
|
e)
|
Date
of the transaction
|
2018-02-16
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr P Thomson
|
|||
|
b)
|
Position/status
|
President, Global Affairs
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2015 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
4,689
(Deferred)
|
|
||
|
|
£0.0000
|
3,235
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
7,924
|
|||
|
Aggregated
volume Price
|
£0.0000
|
||||
|
e)
|
Date
of the transaction
|
2018-02-19
|
|||
|
f)
|
Place
of the transaction
|
n/a
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr P Thomson
|
|||
|
b)
|
Position/status
|
President, Global Affairs
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 19 February 2018 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.1240
|
2,204
(Deferred)
|
|
||
|
|
£13.1240
|
1,521
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
3,725
|
|||
|
Aggregated
volume Price
|
£13.1240
|
||||
|
e)
|
Date
of the transaction
|
2018-02-19
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr P Vallance
|
|||
|
b)
|
Position/status
|
Outgoing President, R&D
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2015 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
20,322
(Deferred)
|
|
||
|
|
£0.0000
|
14,022
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
34,344
|
|||
|
Aggregated
volume Price
|
£0.0000
|
||||
|
e)
|
Date
of the transaction
|
2018-02-19
|
|||
|
f)
|
Place
of the transaction
|
n/a
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr P Vallance
|
|||
|
b)
|
Position/status
|
Outgoing President, R&D
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares following the exercise of options on 19
February 2018 under the Company's Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.1760
|
20,322
(Deferred)
|
|
||
|
|
£13.1760
|
14,022
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
34,344
|
|||
|
Aggregated
volume Price
|
£13.1180
|
||||
|
e)
|
Date
of the transaction
|
2018-02-19
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
20, 2018
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|